APOL1 polymorphism modulates sphingolipid profile of human podocytes-Reference-Cited by-同舟云学术

APOL1 polymorphism modulates sphingolipid profile of human podocytes

Published:2020-09-11 Issue:6 Volume:37 Page:729-744
ISSN:0282-0080
Container-title:Glycoconjugate Journal
language:en
Short-container-title:Glycoconj J

Author:

Valsecchi Manuela,Cazzetta Valentina,Oriolo Ferdinando,Lan Xiqian,Piazza Rocco,Saleem Moin A.,Singhal Pravin C.,Mavilio Domenico,Mikulak Joanna,Aureli Massimo^ORCID

Abstract

AbstractApolipoprotein L1 (APOL1) wild type (G0) plays a role in the metabolism of sphingolipids, glycosphingolipids, sphingomyelin and ceramide, which constitute bioactive components of the lipid rafts (DRM). We asked whether APOL1 variants (APOL1-Vs) G1 and G2 carry the potential to alter the metabolism of sphingolipids in human podocytes. The sphingolipid pattern in HPs overexpressing either APOL1G0 or APOL1-Vs was analysed by using a thin mono- and bi-dimensional layer chromatography, mass-spectrometry and metabolic labelling with [1-3H]sphingosine. HP G0 and G1/G2-Vs exhibit a comparable decrease in lactosylceramide and an increase in the globotriaosylceramide content. An analysis of the main glycohydrolases activity involved in glycosphingolipid catabolism showed an overall decrease in the activeness of the tested enzymes, irrespective of the type of APOL1-Vs expression. Similarly, the high throughput cell live-based assay showed a comparable increased action of the plasma membrane glycosphingolipid-glycohydrolases in living cells independent of the genetic APOL1 expression profile. Importantly, the most significative modification of the sphingolipid pattern induced by APOL1-Vs occurred in DRM resulted with a drastic reduction of radioactivity associated with sphingolipids. G1/G2-Vs present a decrease amount of globotriaosylceramide and globopentaosylceramide compared to G0. Additionally, ceramide at the DRM site and lactosylceramide in general, showed a greatest fall in G1/G2 in comparison with G0. Additionally, the levels of glucosylceramide decreased only in the DRM of human podocytes overexpressing G1/G2-Vs. These findings suggest that altered sphingolipidsprofiles may contribute to the deranged functionality of the plasma membrane in APOL1 risk milieu.

Funder

Foundation for the National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

https://link.springer.com/content/pdf/10.1007/s10719-020-09944-w.pdf

Reference60 articles.

1. Duchateau, P.N., Pullinger, C.R., Orellana, R.E., Kunitake, S.T., Naya-Vigne, J., O'Connor, P.M., Malloy, M.J., Kane, J.P.: Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem. 272(41), 25576–25582 (1997). https://doi.org/10.1074/jbc.272.41.25576

2. Duchateau, P.N., Movsesyan, I., Yamashita, S., Sakai, N., Hirano, K., Schoenhaus, S.A., O'Connor-Kearns, P.M., Spencer, S.J., Jaffe, R.B., Redberg, R.F., Ishida, B.Y., Matsuzawa, Y., Kane, J.P., Malloy, M.J.: Plasma apolipoprotein L concentrations correlate with plasma triglycerides and cholesterol levels in normolipidemic, hyperlipidemic, and diabetic subjects. J. Lipid Res. 41(8), 1231–1236 (2000)

3. Vanhamme, L., Paturiaux-Hanocq, F., Poelvoorde, P., Nolan, D.P., Lins, L., Van Den Abbeele, J., Pays, A., Tebabi, P., Van Xong, H., Jacquet, A., Moguilevsky, N., Dieu, M., Kane, J.P., De Baetselier, P., Brasseur, R., Pays, E.: Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 422(6927), 83–87 (2003). https://doi.org/10.1038/nature01461